Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.9667
-0.0149-1.52%
Post-market: 0.9650-0.0017-0.18%19:34 EDT
Volume:288.31K
Turnover:290.67K
Market Cap:1.44M
PE:-0.01
High:1.06
Open:0.9998
Low:0.9500
Close:0.9816
52wk High:524.00
52wk Low:0.9199
Shares:1.49M
Float Shares:1.48M
Volume Ratio:0.08
T/O Rate:19.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-175.9200
EPS(LYR):-303.4772
ROE:-106.98%
ROA:-53.08%
PB:0.11
PE(LYR):0.00

Loading ...

Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial

Reuters
·
Apr 20

Clearmind Medicine Inc - Cmnd-100 Shows High Safety Profile at Highest Dosage With No Serious Adverse Events

THOMSON REUTERS
·
Apr 20

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

GlobeNewswire
·
Apr 20

Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial

TIPRANKS
·
Apr 16

Clearmind announces DSMB recommendation to continue CMND-100 trial

TIPRANKS
·
Apr 16

Clearmind advances CMND-100 alcohol use disorder trial, raises dose to 160 mg

Reuters
·
Apr 15

Clearmind Medicine Inc - Cmnd-100 Well Tolerated With No Serious Adverse Events in Third Cohort

THOMSON REUTERS
·
Apr 15

Clearmind Medicine Inc - to Proceed to Fourth Cohort, Increase Cmnd-100 Dose to 160Mg

THOMSON REUTERS
·
Apr 15

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in Ongoing Cmnd-100 Clinical Trial

THOMSON REUTERS
·
Apr 15

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

GlobeNewswire
·
Apr 15

Clearmind Medicine issues $1.75 million convertible notes, raises $1.58 million cash

Reuters
·
Apr 15

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere

Reuters
·
Apr 14

BUZZ-Clearmind Medicine rises after alcohol addiction drug shows safety in early trial

Reuters
·
Apr 14

Clearmind Medicine Inc - Third Cohort Results Show High Safety Profile for Cmnd-100 With No Serious Adverse Events

THOMSON REUTERS
·
Apr 14

Clearmind Medicine Inc - Phase I/Iia Trial Evaluates Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Cmnd-100

THOMSON REUTERS
·
Apr 14

Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

GlobeNewswire
·
Apr 14

Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial

TIPRANKS
·
Apr 02

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

GlobeNewswire
·
Mar 30

BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders

Reuters
·
Mar 27

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

THOMSON REUTERS
·
Mar 27